MADRIGAL PHARMACEUTICALS INC

NASDAQ: MDGL (Madrigal Pharmaceuticals, Inc.)

Kemas kini terakhir: semalam, 1:47AM

498.04

1.07 (0.22%)

Penutupan Terdahulu 496.97
Buka 496.97
Jumlah Dagangan 213,542
Purata Dagangan (3B) 359,371
Modal Pasaran 11,311,196,160
Harga / Jualan (P/S) 14.85
Harga / Buku (P/B) 18.00
Julat 52 Minggu
265.00 (-46%) — 615.00 (23%)
Tarikh Pendapatan 4 Nov 2025
Margin Keuntungan -123.38%
Margin Operasi (TTM) -57.79%
EPS Cair (TTM) -17.83
Jumlah Hutang/Ekuiti (D/E MRQ) 16.85%
Nisbah Semasa (MRQ) 5.91
Aliran Tunai Operasi (OCF TTM) -395.31 M
Aliran Tunai Bebas Leveraj (LFCF TTM) -274.11 M
Pulangan Atas Aset (ROA TTM) -25.56%
Pulangan Atas Ekuiti (ROE TTM) -50.16%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Biotechnology (US) Menaik Bercampur
Biotechnology (Global) Menaik Bercampur
Stok Madrigal Pharmaceuticals, Inc. Menaik Menaik

AISkor Stockmoo

-0.7
Konsensus Penganalisis 1.5
Aktiviti Orang Dalam -1.5
Volatiliti Harga -0.5
Purata Bergerak Teknikal -2.5
Osilator Teknikal -0.5
Purata -0.70

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
MDGL 11 B - - 18.00
BBIO 15 B - - -
EXEL 12 B - 18.83 5.43
PRAX 9 B - - 24.04
TGTX 5 B - 11.04 8.16
CORT 4 B - 42.02 5.78

Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.

Sektor Healthcare
Industri Biotechnology
Gaya Pelaburan Small Growth
% Dimiliki oleh Orang Dalam 7.73%
% Dimiliki oleh Institusi 108.28%

Pemilikan

Nama Tarikh Syer Dipegang
Paulson & Co. Inc. 30 Sep 2025 1,907,523
Julat 52 Minggu
265.00 (-46%) — 615.00 (23%)
Julat Harga Sasaran
445.00 (-10%) — 900.00 (80%)
Tinggi 900.00 (Piper Sandler, 80.71%) Beli
Median 645.00 (29.51%)
Rendah 445.00 (B of A Securities, -10.65%) Pegang
Purata 657.13 (31.94%)
Jumlah 7 Beli, 1 Pegang
Harga Purata @ Panggilan 530.03
Syarikat Tarikh Harga Sasaran Panggilan Harga @ Panggilan
Citizens 20 Jan 2026 745.00 (49.59%) Beli 504.95
05 Nov 2025 527.00 (5.81%) Beli 475.87
Piper Sandler 19 Dec 2025 900.00 (80.71%) Beli 591.02
B. Riley Securities 11 Dec 2025 670.00 (34.53%) Beli 571.33
HC Wainwright & Co. 21 Nov 2025 620.00 (24.49%) Beli 547.96
11 Nov 2025 568.00 (14.05%) Beli 541.50
Oppenheimer 20 Nov 2025 650.00 (30.51%) Beli 542.12
Truist Securities 19 Nov 2025 640.00 (28.50%) Beli 555.60
Canaccord Genuity 13 Nov 2025 587.00 (17.86%) Beli 514.93
B of A Securities 03 Nov 2025 445.00 (-10.65%) Pegang 412.35
Nama Purata Belian ($) Purata Jualan ($) Jumlah Net Jumlah Nilai Bersih ($)
KELLEY SHANNON T - 504.95 -692 -349,425
TAUB REBECCA - 504.95 -2,238 -1,130,078
THAKKAR RITA 495.88 - 2,398 1,189,120
Jumlah Keseluruhan Kuantiti Bersih -532
Jumlah Keseluruhan Nilai Bersih ($) -290,383
Purata Pembelian Keseluruhan ($) 495.88
Purata Jualan Keseluruhan ($) 504.95
Julat Insider ($)
495.88 (-0%) — 504.95 (1%)
Nama Pemegang Tarikh Jenis Kuantiti Harga Nilai ($)
TAUB REBECCA Pengarah 20 Jan 2026 Jual (-) 2,238 504.95 1,130,078
KELLEY SHANNON T Pegawai 20 Jan 2026 Jual (-) 263 504.95 132,802
KELLEY SHANNON T Pegawai 20 Jan 2026 Jual automatik (-) 429 504.95 216,624
THAKKAR RITA Pegawai 15 Jan 2026 Diperolehi (+) 2,398 495.88 1,189,120
Tarikh Jenis Butiran
22 Jan 2026 Pengumuman Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
21 Jan 2026 Pengumuman Madrigal Pharmaceuticals Announces Grant of Inducement Award under Nasdaq Listing Rule 5635(c)(4)
09 Jan 2026 Pengumuman Madrigal Expands its MASH Pipeline with Exclusive Global License Agreement for Ervogastat, a Phase 2 Oral DGAT-2 Inhibitor
02 Jan 2026 Pengumuman Gene Therapy: 5 Biotech Stocks Chasing the $36B Prize
18 Dec 2025 Pengumuman Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
15 Dec 2025 Pengumuman Madrigal Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
04 Dec 2025 Pengumuman Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
20 Nov 2025 Pengumuman Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
17 Nov 2025 Pengumuman Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences
10 Nov 2025 Pengumuman Madrigal Presents New Data Demonstrating Rezdiffra® (resmetirom) Significantly Improved Multiple Noninvasive Imaging Tests and Biomarkers in Patients with Compensated MASH Cirrhosis
06 Nov 2025 Pengumuman Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
04 Nov 2025 Pengumuman Madrigal Pharmaceuticals Reports Third-Quarter 2025 Financial Results and Provides Corporate Updates
28 Oct 2025 Pengumuman Madrigal to Present New Data from the Company’s MASH Program at AASLD’s The Liver Meeting 2025
Papar semua

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2026 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda